Sign in
- You are currently accessing unquote.com via your Enterprise account.
  
  If you already have an account please use the link below to sign in.
  
  If you have any problems with your access or would like to request an individual access account please contact our customer service team.
  
  Phone: +44 (0)203 741 1137
  
  Email: Georgina.Lawson@acuris.com
  - Sign in
Follow us
- Twitter
- LinkedIn
Free Trial
Subscribe

Seventure and CM-CIC’s Biophytis to raise €20m via IPO

José Rojo
29 June 2015

Tweet
Facebook
LinkedIn
Google plus
Send to

Biophytis, a French age-related medical drug developer backed by Seventure Partners and CM-CIC Partners, is aiming to raise €19.9m with its upcoming listing on Alternext.

The flotation, expected to take place between 29 June and 7 July, has an indicative price range of €6-8.1 per share.

Arranged by bookrunner Invest Securities, the offering comprises 2,230,000 new shares, together representing a capital increase of €15.7m.

Should the extension clause and the over-allotment option be fully exercised, a further maximum of 334,500 and 384,675 shares will be sold, respectively. This would increase potential proceeds to €19.9m.

Seventure Partners and CM-CIC currently hold a combined 49.29% stake in Biophytis, the former's 24.77% leading by a short margin over the latter's 24.52%. Should the IPO go forward, Seventure is expected to retain a minimum of 15.57%, while CM-CIC would keep 15.4%, together representing a 30.97% shareholding.

The flotation is the second by a private equity-backed French healthcare business in the past few days. Last Friday, Apax France-owned orthopaedic implant designer Amplitude Surgical listed on Euronext Paris with a €234.6m market cap.

Founded by Stanislas Veillet in 2006, Biophytis is a pharmaceuticals and research company. It specialises in the development of drugs derived from nutraceutical active substances, which are used in treatments of metabolic and age-related diseases.

Headquartered in Romainville, France, the business currently operates a subsidiary in Sao Paulo, Brazil, and works in partnership with research institutions including UPMC, ICAN, l'Institut de Myologie and l'Institut de la Vision.

Seventure and CM-CIC have been shareholders in Biophytis since June 2009, when they injected a combined €3m into the business.

In October 2012, the duo were joined by research centre Metabrain Research for a €2m series-B round for the pharmaceutical company. According to unquote" data, the firm's contribution for the round was around the €800,000 mark.